According to the TOURMALINE-MM1 trial, ixazomib, LEN, and dexamethasone improved PFS compared with Rd in patients with myeloma and a high expression of the c-MYC gene, although LEN-refractory myeloma patients were excluded from this trial [32]. Here, MYC is linked to plasma cell myeloma.